Monoclonal antibody HCV‐AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study

Thomas D. Schiano, Michael Charlton, Zobair Younossi, Eithan Galun, Timothy Pruett, Ran Tur‐Kaspa, Rachel Eren, Shlomo Dagan, Neil Graham, Paulette V. Williams, John Andrews – 24 August 2006 – A randomized, double‐blind, dose‐escalation study evaluated the safety and efficacy of hepatitis C virus (HCV)‐AbXTL68, a neutralizing, high‐affinity, fully human, anti‐E2 monoclonal antibody, in 24 HCV‐positive patients undergoing liver transplantation.

Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection

Atsushi Ozasa, Yasuhito Tanaka, Etsuro Orito, Masaya Sugiyama, Jong‐Hon Kang, Shuhei Hige, Tomoyuki Kuramitsu, Kazuyuki Suzuki, Eiji Tanaka, Shunichi Okada, Hajime Tokita, Yasuhiro Asahina, Kazuaki Inoue, Shinichi Kakumu, Takeshi Okanoue, Yoshikazu Murawaki, Keisuke Hino, Morikazu Onji, Hiroshi Yatsuhashi, Hiroshi Sakugawa, Yuzo Miyakawa, Ryuzo Ueda, Masashi Mizokami – 26 July 2006 – The outcome of acute hepatitis B virus (HBV) infection is variable, influenced by host and viral factors.

The liver X‐receptor alpha controls hepatic expression of the human bile acid–glucuronidating UGT1A3 enzyme in human cells and transgenic mice

Mélanie Verreault, Kathy Senekeo‐Effenberger, Jocelyn Trottier, Jessica A. Bonzo, Julie Bélanger, Jenny Kaeding, Bart Staels, Patrick Caron, Robert H. Tukey, Olivier Barbier – 26 July 2006 – Glucuronidation, an important bile acid detoxification pathway, is catalyzed by enzymes belonging to the UDP‐glucuronosyltransferase (UGT) family. Among UGT enzymes, UGT1A3 is considered the major human enzyme for the hepatic C24‐glucuronidation of the primary chenodeoxycholic (CDCA) and secondary lithocholic (LCA) bile acids.

Subscribe to